Cytokinetics Awards Inaugural Communications Fellowship To The ALS Association Golden West Chapter
August 28 2018 - 8:30AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that The
ALS Association Golden West Chapter is the inaugural recipient of
the Cytokinetics Communications Fellowship, an annual grant from
the company intended to support increased capacity and community
engagement for nonprofit organizations.
“As a longstanding partner of the disease and
patient advocacy community, we recognized a need for organizations
to expand the scope of their communications to support families
with rare diseases of muscle dysfunction and we sought an
opportunity to close that gap,” said Diane Weiser, Cytokinetics’
Vice President of Corporate Communications and Investor Relations.
“By providing this Fellowship, our partners will now have funding
to invest in additional communications resources to educate their
communities about their disease and organization, provide
additional support and services, and create connections among
patients, caregivers and advocacy resources.”
“We are extremely grateful to Cytokinetics and
honored to receive this unique grant,” said Fred Fisher, MSW,
President and CEO of The ALS Association Golden West Chapter.
“There are more people than ever who are registering with the
Golden West Chapter, and the demand for the services and support
that we offer grows larger every month. The Fellowship provides
critically-needed funding to help us invest in communications
resources to support people with ALS and their loved ones, and to
create deeper connections between The ALS community and the
Chapter.”
The Fellowship program will be awarded annually
to nonprofit organizations to provide funding support to elevate
the patient’s voice at the grassroots level, build greater
awareness of programs and care services, and extend their outreach
in the communities they serve. Organizations applying for the grant
are required to submit a detailed proposal for activities and
services to be fulfilled and recipients are responsible for
providing an outcomes report to Cytokinetics to measure impact at
the end of the funding period.
About ALS
Amyotrophic lateral sclerosis (ALS) is a
progressive neurodegenerative disease that afflicts approximately
30,000 people in the United States and a comparable number of
patients in Europe. Approximately 6,000 new cases of ALS are
diagnosed each year in the United States. The average life
expectancy of an ALS patient is approximately three to five years
after diagnosis and only 10 percent of patients survive for more
than 10 years. Death is usually due to respiratory failure because
of diminished strength in the skeletal muscles responsible for
breathing. Few treatment options exist for these patients,
resulting in a high unmet need for new therapies to address
functional deficits and disease progression. For more information
about ALS and The ALS Association Golden West Chapter, please visit
www.alsagoldenwest.org
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics is collaborating
with Amgen Inc. (“Amgen”) to develop omecamtiv
mecarbil, a novel cardiac muscle activator. Omecamtiv
mecarbil is the subject of GALACTIC-HF, an international Phase
3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization
in Europe and certain other
countries. Cytokinetics is collaborating
with Astellas Pharma Inc. (“Astellas”) to
develop reldesemtiv (CK-2127107), a next-generation fast
skeletal muscle troponin activator
(FSTA). Reldesemtiv has been granted orphan drug
designation by the FDA for the potential treatment of
spinal muscular atrophy. Reldesemtiv was the subject of a positive
Phase 2 clinical study in patients with spinal muscular atrophy
which showed increases in measures of endurance and stamina
consistent with the mechanism of action. Reldesemtiv is currently
the subject of two ongoing Phase 2 clinical trials in patients with
chronic obstructive pulmonary disease and amyotrophic lateral
sclerosis. Astellas is also conducting a Phase 1b clinical trial of
reldesemtiv in elderly adults with limited mobility. Astellas
holds an exclusive worldwide license to develop and
commercialize reldesemtiv. Licenses held
by Amgen and Astellas are subject
to Cytokinetics' specified co-development and
co-commercialization rights. Cytokinetics continues its
20-year history of innovation with three new muscle biology
directed compounds advancing from research to development in 2018.
For additional information about Cytokinetics,
visit www.cytokinetics.com.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' and its partners'
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics' business outlined in Cytokinetics'
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane WeiserVice President,
Corporate Communications, Investor Relations(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024